StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — Shrikant Chouhan, Kotak Securities

BUYDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

byShrikant Chouhan, Kotak SecuritiesHorizon: NA (inferred 1–3 months)28 Jul 2026via Business Standard Markets

Entry₹1,820Stated
Target₹2,030
Total upside +11.54% (call closed)
Stop lossNot given
Exit₹2,03016 Sept 2026, 12:09 pm
Target hit+11.54%0.00%upside left
Follow Shrikant Chouhan for new calls(42% target hit, 24 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 2 active Short-term calls on LALPATHLABSee 39 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 16 Sept 2026
13 supporting1 neutral0 opposing
Supports the BUY call (13)

Indian Diagnostic Giants Post Strong Q1 FY27 Growth Amid Stable Pricing

NewsGoogle News·13 Sept · 2d ago

(opens in new tab)

1 advisor has an active long-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·7 Sept · 1w ago

Dr. Lal Ventures Private Limited, a wholly-owned subsidiary, has completed the subscription of a 30% stake in Neuome Technologies Private Limited. Neuome now becomes an associate of the company.

BSE · Company Update·27 Aug · 3w ago

(opens in new tab)

2 other SEBI-registered advisors have active short-term BUY calls on this stock

Advisor consensus · same horizon·19 Aug · 4w ago

Shri Bajrang Alliance Annual Report: Profit Up, Capacity Expansion Approved

NewsGoogle News·17 Aug · 4w ago

(opens in new tab)
Neutral / worth noting (1)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from Shrikant Chouhan, Kotak Securities

Every call and its outcome